Abstract
Estrogenic hormones possess both immunostimulating and immunosuppressive properties. In systemic lupus erythematosus (SLE), pregnancy is associated with disease flares. In some situations, exogenous estrogen predisposes to development of new SLE, flares of preexisting SLE, and thromboses in susceptible individuals. In contrast, treatment with exogenous estrogen protects postmenopausal rheumatoid arthritis (RA) patients from active RA and osteoporosis. The search for estrogen-like compounds with anti-inflammatory properties may expand treatment options in RA.
Similar content being viewed by others
References
Nalbandian G, Kovats S (2005) Estrogen, immunity & autoimmune disease. Curr Med Chem 5:85–91
Cutolo M, Capellino S, Sulli A et al (2006) Estrogens and autoimmune disease. Ann NY Acad Sci 1089:538–547
Lang TJ (2004) Estrogen as an immunomodulator. Clin Immunol 113:224–230
Cohen-Solal JFG, Jeganathan L, Kawabata D et al (2008) Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 17:528–532
Petri M (2008) Sex hormones and systemic lupus erythematosus. Lupus 17:412–415
Maul RW, Gearhart PJ (2009) Women, autoimmunity, and cancer: a dangerous liaison between estrogen and activation-induced deaminase? J Exp Med 206:11–13
Shim G-J, Kis LL, Warner M et al (2004) Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 101:1720–1724
Bynote KK, Hackenbert JM, Korach KS et al (2008) Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB × NZW)Fl mice. Genes Immun 9:137–152
McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270
Steinberg AD, Steinberg BJ (1985) Lupus disease activity associated with menstrual cycle. J Rheumatol 12:816–817
Mok CC, Lau CS, Ho CT et al (1999) Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 28:357–362
Mok CC, Wong RW, Lau CS et al (1999) Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42:1274–1280
Costenbader KH, Feskanich D, Stampfer MJ et al (2007) Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56:1251–1262
Walker SE (2007) The importance of sex hormones in lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 7th edn. Williams & Wilkins, Baltimore, pp 273–285
Cooper GS, Dooley MA, Treadwell EL et al (2002) Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Results of a population-based, case–control study. Arthritis Rheum 46:1830–1839
Ostensen M (1999) Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann NY Acad Sci 876:131–143
Doria A, Iaccarino L, Sarzi-Puttini P et al (2006) Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci 1069:247–256
Sanchez-Guerrero J, Karlson EW, Liang MH et al (1997) Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthrits Rheum 40:804–808
Bl S, Reidenberg MM, West S et al (1994) Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 140:632–642
Petri M, Kim MY, Kalunian KC, Grossman J et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 353:2550–2558
Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539–2549
US Preventive Services Task Force (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Int Med 142:885–860
Sanchez-Guerrero J, Liang MH, Karlson EW et al (1995) Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Int Med 122:430–433
Barrett C, Neylon N, Snaith ML (1986) Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 25:300–301
Calvo-Alen FM, Bertoli AM, Bastian HM et al (2007) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 13:261–265
Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Darbajal M et al (2007) Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 56:3070–3079
Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Int Med 142:953–962
Grady D, Herrington D, Bittner V et al (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
Huong DLT, Wechsler B, Piette J-C et al (1996) Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 35:1184–1186
Casoli P, Tumiati B, La Sala G (1997) Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 24:1639–1640
Guballa N, Sammaritano L, Schwartzman S et al (2000) Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 43:550–556
Du LTH, Wechsler B, Piette J-C (2003) Induction d’ovulation et lupus. Ann Med Interne 154:45–50
Silva CAA, Leal MM, Leone C et al (2002) Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 11:419–425
Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436–441
Cutolo M, Lahita RG (2005) Estrogens and arthritis. Rheum Dis Clin N Am 31:19–27
Auborn KJ, Qi M, Yan XJ et al (2003) Lifespan is prolonged in autoimmune-prone (NZB/NZW) mice fed a diet supplemented with indole-3-carbinol. J Nutr 133:3610–3613
Apelgren LD, Bailey DL, Fouts RS et al (1996) The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRLlpr/lpr mice. Cell Immunol 173:55–63
Sthoeger ZM, Zinger H, Mozes E (2002) Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62:341–346
Peeva E, Venkatesh J, Diamond B (2005) Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 75:1415–1423
Greenstein BD, Dhaher YY, de Bridges EF (1993) Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice. Lupus 2(2):221–225
Rose E, Pillsbury DM (1944) Lupus erythematosus (erythematodes) and ovarian function: observations on a possible relationship, with report of six cases. Ann Int Med 21:1022–1034
Laroche M, Borg S, Lassoued S, De Lafontan B et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34:2259–2263
Cheong JL, Bucknall R (2009) Retinal vein thrombosis associated with a herbal phytoesrogen preparation in a susceptible patient. Postgrad Med J 81:266–267
Bhattoa HP, Bettembuk P, Balogh A et al (2004) The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic, postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 15:396–404
Sturgess AD, Evans DT, Mackay IR et al (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14
Mok CC, To CH, Mak A et al (2005) Raloxifene for postmenopausal women with systemic lupus erythematosus. A pilot randomized controlled study. Arthritis Rheum 52:3997–4002
Rider V, Li X, Peterson G, Dawson J et al (2006) Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33:1093–1101
Lee YJ, Shin KS, Kang SW et al (2004) Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 63:1244–1249
Johansson M, Arlestig L, Moller B et al (2005) Oestrogen receptor alpha gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 64:1611–1617
Abdou NI, Rider V, Greenwell C et al (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797–803
Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609
Brahn E, Banquerigo MN, Lee JK et al (2008) An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 35:2119–2128
Shoenfeld Y, Zangman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. IMAJ 10:8–12
Gerosa M, De Angelis V, Riboldi et al (2008) Rheumatoid arthritis: a female challenge. Women’s Health 4:195–201
Sokka T, Toloza S, Cutolo M et al (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arth Res Ther 11:R7
Straub RH, Harle P, Atzeni F et al (2005) Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 32:1253–1257
Rovensky J, Kvetnansky R, Radikova Z et al (2005) Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 23:292–296
Capellino S, Montagna P, Villaggio B et al (2007) Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 26:904–909
Capellino S, Riepl B, Rauch L et al (2006) Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 66:53–58
Spector TD, Hochberg MC (1989) The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 28(Suppl):11–12
Hall GM, Daniels M, Huskisson EC et al (1994) A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53:112–116
MacDonald AG, Murphy EA, Capell HA et al (1994) Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 53:54–57
Forsblad d’Elia H, Larsen A, Mattsson L et al (2003) Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheum 30:1456–1463
Forsblad d’Elia H, Mattsson L, Ohlsson C et al (2003) Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor I. Arth Res Ther 5:R202–R209
Forsblad d’Elia H, Carlsten H (2008) The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol 68:661–667
Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411
Jochems C, Lagerquist M, Hakansson C et al (2008) Long-term anti-arthritis and anti-osteopenic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 152:593–597
Harnish DC (2006) Estrogen receptor ligands in the control of pathogenic inflammation. Internat Immunol 6:1413–1423
Carlsten H (2007) Interaction with estrogen receptors as treatment of arthritis and osteoporosis. In: Choi Y (ed) Osteoimmunology. Springer, New York, pp 83–92
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walker, S.E. Estrogen and Autoimmune Disease. Clinic Rev Allerg Immunol 40, 60–65 (2011). https://doi.org/10.1007/s12016-010-8199-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-010-8199-x